Achieve Life Sciences (ACHV) Income from Continuing Operations (2010 - 2018)
Achieve Life Sciences (ACHV) recorded quarterly Income from Continuing Operations of 3637000.0 in Q4 2018, down 12.25% on a QoQ basis from 3240000.0 in Q3 2018, and up 2.75% year-over-year from 3539521.21 in Q4 2017.
Achieve Life Sciences (ACHV) Income from Continuing Operations (2010 - 2018) Analysis & Trends
Achieve Life Sciences has disclosed Income from Continuing Operations across 7 years of filings, most recently posting 3637000.0 for Q4 2018.
- Quarterly Income from Continuing Operations rose 2.75% year-over-year to 3637000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was 12687000.0 (up 6.95% YoY) and the FY2019 annual result came in at 16395000.0, down 29.23% from the prior year.
- Income from Continuing Operations eased to 3637000.0 in Q4 2018, from 3240000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 166000.0 in Q2 2017 and troughed at 9400000.0 in Q3 2017.
- A 4-year average of 2597727.27 and a median of 2788000.0 in 2018 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2017 — Income from Continuing Operations sank 2220.99% — and 2018, when it soared 65.53%.
- Tracing ACHV's Income from Continuing Operations over 4 years: stood at 1235000.0 in 2015, then jumped by 50.36% to 613000.0 in 2016, then slumped by 510.11% to 3740000.0 in 2017, then advanced by 2.75% to 3637000.0 in 2018.
- Business Quant data shows ACHV's Income from Continuing Operations at 3637000.0 in Q4 2018, 3240000.0 in Q3 2018, and 2788000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -3.64 Mn |
| Sep 30, 2018 | -3.24 Mn |
| Jun 30, 2018 | -2.79 Mn |
| Mar 31, 2018 | -3.02 Mn |
| Dec 31, 2017 | -3.74 Mn |
| Sep 30, 2017 | -9.40 Mn |
| Jun 30, 2017 | -166,000.00 |
| Mar 31, 2017 | -329,000.00 |
| Dec 31, 2016 | -613,000.00 |
| Sep 30, 2016 | -405,000.00 |
| Dec 31, 2015 | -1.24 Mn |
| Dec 31, 2012 | -38.09 Mn |
| Sep 30, 2012 | 5.92 Mn |
| Jun 30, 2012 | 4.22 Mn |
| Mar 31, 2012 | -6.86 Mn |
| Dec 31, 2011 | -19.78 Mn |
| Sep 30, 2011 | -4.47 Mn |
| Jun 30, 2011 | 6.53 Mn |
| Mar 31, 2011 | -3.05 Mn |
| Dec 31, 2010 | -2.80 Mn |